Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14

Simon H. Murch
Emeritus Professor, Warwick Medical School, University of Warwick, Coventry, UK

ABSTRACT

SARS-CoV-2 interaction with the ACE-2 receptor cannot alone explain the demography and remarkable variation in clinical progression of Covid-19 infection. Unlike SARS-CoV, the cause of SARS, several SARS-CoV-2 spike glycans contain sialic acid residues. In contrast to the SARS secreted glycoprotein (SGP), SARS-CoV-2 SGP are thus potential ligands for Sialic acid-binding Siglecs on host immune cells, known to regulate immune function. Such SARS-CoV-2 glycoproteins would contribute to immune deviation.

CD33-related Siglecs are important immune regulators. Siglec-5 and −14 are paired receptors with opposed actions on the NLRP3 inflammasome, which is critical in early viral clearance. SGP binding in persons of Siglec-14 null genotype (30–70% in Black, Asian and Minority Ethnic (BAME) persons, 10% in North Europeans) would induce unopposed inhibitory signalling, causing viral persistence through inflammasome inhibition.

Siglec-3 (CD33) and Siglec-5 are expressed on CD33 myeloid derived suppressor cells (CD33 MDSC). Immunosuppressive CD33 MDSC populations are increased in all groups at risk of severe Covid-19 infection. CD33 expression is increased in persons with the CD33 rs3865444 CC allele, associated with Alzheimer’s disease, who would thus show enhanced susceptibility. Viral SGP ligation of CD33, potentially in conjunction with Siglec-5, would promote expansion of CD33 MDSC cells, as occurs in cancers but at much greater scale.

CD33 is expressed on CNS microglia, potentially activated by SGP penetration through the porous cribriform plate to cause anosmia.

Genotyping of severe or fatal Covid-19 cases can confirm or refute this pathophysiological mechanism. Early data have confirmed extremely high-level increase of CD33 MDSC numbers in severe Covid-19 infection, consistent with the proposed mechanism.

Susceptibility to severe Covid-19 infection

The variability of Covid-19 infection is remarkable, with responses ranging from asymptomatic clearance to death. The course of disease in symptomatic persons may be unusually prolonged.

The primary tropism of the SARS-CoV-2 virus is for angiotensin converting enzyme-2 (ACE-2), which is expressed on lung and intestinal epithelium and in heart, kidney, pancreas and brain. Widespread viral infection may thus induce multisystem inflammation, augmented by disruption of the renin-angiotensin system [1].

Several factors have emerged as associated with severe or persistent disease, including old age, diabetes, hypertension, COPD, cigarette smoking, previous or current cancer, dementia and ethnicity [2]. A theory of pathogenesis based solely on variation in ACE-2 receptor expression and targeted inflammation cannot explain many of these demographic features of Covid-19 susceptibility, the phenomenon of prolonged viral persistence or the features of ongoing disease such as late-onset cytokine storm and frequent vascular thromboses.

Potential binding of SARS-CoV-2 secreted glycans to CD33-related Siglecs

The demography of severe disease is compatible with a known viral mechanism, binding of sialylated secreted glycans to host sialic acid-binding immunoglobulin-type lectins (Siglecs) [3]. This interaction can allow immune evasion and immunosuppression [4]. Siglec binding glycans are common amongst RNA viruses, including Siglec-1 binding of macrophages by Betaarterivirus suid in Porcine Reproductive and Respiratory Syndrome [4]. Both HIV and Ebola viruses bind Siglec-1 [4]. So far, there have not been reports of viral interactions with the family of CD33-related (CD33-r) Siglecs.

CD33-r Siglecs are a subgroup of Siglecs of quite homologous structure which show evidence of unusually rapid evolution in all pri mate species [5,6]. They recognise Self Associated Molecular Patterns (SAMPS), which themselves have to evolve to evade targeting by sialic acid expressing pathogens while maintaining self-recognition. There are marked inter-species differences between primates in CD33-r Siglec expression and this group of Siglec receptors have been postulated to be at the forefront of an evolutionary arms race between pathogens and
hosts [6]. Pathogens expressing sialylated residues can interact with CD33-r Siglecs to modulated host immune responses. This is so far best recognised in bacteria, notably group B streptococcus (GBS), which binds to Siglec-5 and −14 via its surface β-protein, through which it modulates neutrophil responses [4]. In humans, Siglecs 3 (CD33) and 5 are co-expressed on monocytes, macrophages and neutrophils while dendritic cells are Siglec 3′ 5′ [4]. Siglec-14 is expressed on monocytes, macrophages and neutrophils.

CD33 is additionally expressed on CNS microglia [7], while Siglec-5 is expressed on amniotic epithelium and plays a role in GBS-induced preterm delivery [8].

**Known ligands of CD33-related Siglecs**

Many sialolactosamine (SLL) carbohydrate motifs have been shown to bind to CD33-r Siglecs, including 6′-SLL (Neu5Acα2-6Galβ1-4Glc), 3′-SLL (Neu5Acα2-3Galβ1-4Glc) and 3′-SLacNAc (Neu5Acα2-3Galβ1-4GlcNAc) ligands [9]. Siglec-5 binds equally to 6′-SLL, 3′-SLL and 3′-SLacNAc ligands while Siglec-3 (CD33) binds preferentially to 6′-SLL with lesser avidity for 3′-SLL and 3′-SLacNAc [9]. Thus, a single sialylated ligand can potentially signal through both CD33 and Siglec-5. Siglec-14 binding will be identical to Siglec-5 due to the common extracellular domain.

An additional sialylated carbohydrate motif, associated with shorter glycan chain and less microheterogeneity, is found in sialyl-Tn glycans. Both CD33 and Siglec-5 are significantly bound by sialyl-Tn [6,9]. Sialyl Tn glycan binding is a functionally important modulator of CD33 signalling, as identified for HIV envelope glycoprotein Gp120 [3].

SARS-CoV-2 has 16 N-linked glycans between the S1 subunit, which binds the angiotensin-2 receptor, and the S2 subunit, which mediates membrane fusion [10]. Glycosylation mapping has identified N-glycans terminating in 3′-SLacNAc structures at N234 and N282 on spike-1 and N1098 on spike-2, while the O-glycan at T323 shows sialic acid capped chains, including sialyl T antigen and di-sialyl core 1, trimmable to sialyl Tn [11,12]. This represents a fundamental difference to SARS-CoV, where glycans show negligible sialylation.

The major SARS-CoV glycoprotein, mediating membrane fusion for viral entry in SARS, is also released into the circulation in soluble form [13]. Similar release through cleavage would allow SARS-CoV-2 sialylated secreted glycoproteins (SGP) to modulate immune response through CD33-r Siglecs. In particular, such interaction with Siglec-3, −5 and −14 would explain specific features of the demography and pathogenesis of Covid-19 infection.

**Potential consequence of Siglec 14 null polymorphism in Covid-19 infection**

Siglec-5 and Siglec-14 are paired regulators of the Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing-3 (NLRC3) inflammasome, which responds to danger signals in infection by production of inflammatory mediators (Fig. 1) [14]. While unregulated NLRC3 inflammasome activation may contribute to damaging inflammatory responses in chronic infection, it is critical in the early response to infection necessary for viral eradication: viruses including Epstein-Barr virus and Zika virus have developed immune evasion strategies by inhibiting the NLPR3 inflammasome [14,15].

Siglec-5 and −14 are paired receptors, having essentially identical extracellular binding domains but differing intracellular signalling pathways [8]. Siglec-5 associates with tyrosine phosphatase SHP-1 to send an inhibitory signal upon ligation, while Siglec-14 associates with the adapter protein DAP-12 and the tyrosine kinase Syk to send an activating signal. Thus Siglec-5 binding downregulates NLRC3 inflammasome activity, while Siglec-14 binding upregulates it [8,16]. Importantly, there is a common polymorphism, in which Siglec-14 is replaced by a Siglec-5 like fusion protein (Siglec 14/5) signalling via the inhibitory SHP-1 pathway identically to Siglec-5 [17]. Individuals can express both Siglec-5 and −14 (Siglec-14+/-), can have one allele where Siglec-14 is replaced by 14/5 (Siglec-14−/−) heterozygous) or have both alleles where Siglec-14 is replaced by 14/5 (Siglec-14−/-, known as Siglec-14 Null allele) [18].

Thus, persons with Siglec-14 Null allele receive an inhibitory input to the NLRP3 inflamasome upon Siglec-5 binding while those without have a stimulatory input, greater in Siglec-14−/− homozygotes than heterozygotes (Fig. 1) [16,18]. There are recognised functional consequences. Adults with the Siglec-14 null allele are at reduced risk for infective exacerbation of COPD [18] and may be less susceptible to severe tuberculosis [19]. Conversely Siglec-14 null women are at increased risk of premature delivery if infected with GBS [17].

There is substantial ethnic variation in Siglec-14 null allele, with a frequency of 50–70% in Chinese, South East Asians and Middle Eastern persons, 30–40% in Indo-Pakistanis and Sub-Saharan Africans and only 10% in Northern Europeans [9]. The pathogen drive currently or previously underlying such major variability remains so far unknown.

The NLRP3 inflammasome is a critical element in effective antiviral responses and its inhibition by pathogens an important cause of immune evasion, as seen in Zika virus infection [14,15]. Binding of SARS-CoV-2 SGP to Siglec-5 would allow such immune evasion in persons of Siglec-14 null genotype through inflammasome inhibition. Newly recruited monocytes would be susceptible to similar inflammasome inhibition. Siglec-14 null women would also be more prone to preterm labour with Covid-19, as occurs if GBS colonised [8].

This mechanism would put persons of origin from China or the Far East, the Middle East, the Indian subcontinent and Sub-Saharan Africa at increased risk of inability to clear SARS-CoV-2 virus upon initial exposure and thus of more severe and chronic disease.

**Increase of Siglec-3 (CD33) expressing MDSC in Covid-19 vulnerable groups**

Both Siglec-3 (CD33) and Siglec-5 are expressed on myeloid-derived suppressor cells (MDSC), important mediators of immune evasion and immunosuppression [20,21]. MDSC are recently recognised cells, best studied in cancer, where they have been described as the Queen Bee in the tumour microenvironment [20]. They are increased in persons with cancer, and remain increased in remission [22]. In cancer, they are induced by direct contact notably dependant on sialyl-Tn ligands, playing a central role in tumour induced suppression of the immune system. Thus sialyl-Tn monoclonal antibodies are receiving increasing attention as potential therapy for cancers [20].

CD33+ MDSC populations release Arginase-1 to cause arginine depletion, inducing decreased T cell receptor (TCR)-ζ chain expression and impaired adaptive immune responses [20,21]. They also release the immunosuppressive cytokines TGF-β and IL-10, as well as effector molecules such as nitric oxide and reactive oxygen metabolites. In addition B cell proliferation and antibody production are diminished by MDSC activation [23].

CD33 MDSC populations are not restricted to cancer, and are increased in a number of other conditions. Indeed, in all other conditions known to be associated with increased Covid-19 mortality, circulating CD33+ MDSC are increased. Significant increase is seen in persons aged 61–76, compared to those aged 19–59, with further increase in frail elderly [22].

Increased CD33 + MDSC numbers in cancer are associated with decreased TCR-ζ expression, contributing to compromised anti-tumour responses [24]. CD33+ HLA-DRlow/+ CD33+ MDSC cells are significantly increased in obesity, associated with decreased TCR-ζ expression [25]. Type-2 diabetes mellitus and arterial hypertension cause increased circulating CD33+ MDSC cells producing immunosuppressive TGF-β and IL-10 [26]. Circulating CD33+ HLA-DR+ MDSC are upregulated in smokers with or without chronic obstructive pulmonary disease (COPD) [27]. In COPD this persists after stopping smoking, associated with
significant downregulation of TCR-ζ expression [27]. Stopping smoking reduces CD33 + MDSC numbers.

Persons with dementia, likely to have high age-related CD33 MDSC, have increased frequency of the CD33 rs3865444 CC allele which upregulates CD33 expression on microglia and immune cells [7]. Monoctye expression of CD33 is upregulated 7-fold in young persons carrying this allele, which explains over 70% of variance in CD33 cell expression [28]. While its putative role in dementia is that this CD33 variant impairs protective uptake of β-amyloid, the relevance of this allele in CD33 rs3865444 CC carriers of whatever age in Covid-19 infection would likely be of increased response by MDSC and monocytes to a CD33-binding viral SGP. This may therefore be a second genetic predisposition to severe Covid-19 infection.

Potential consequences of CD33 MDSC expansion by SARS-CoV-2 SGP

The excess of CD33 MDSC in persons with older age or frailty, diabetes, hypertension, COPD, cancer or previous malignancy or in those who smoke cigarettes would put them at risk of expansion of the MDSC populations by a SARS-CoV-2 Siglec-binding SGP. This would cause an inappropriate immunosuppressive response to SARS-CoV-2 infection. Persons with dementia in care homes would be at particular risk.

CD33 MDSC activation by SARS-CoV-2 SGP would lead to inhibition of both T cell and B cell responses through release of Arginase-1, depleting arginine, and the immunosuppressive cytokines TGF-β and IL-10. Release of reactive oxygen radicals and nitric oxide would contribute to tissue damage (Fig. 2). The overall impact of this phase of infection would be paralysis of adaptive immune responses.

There is evidence that persistent elevation of monocytic MDSC cells, identified as CD14+ HLA-DRlow, is strongly associated with worse outcome in septic shock [29]. CD14+ HLA-DRlow cells have been identified at high frequency in cases of severe Covid-19 infection with immune dysregulation [30]. Further characterisation would be required to determine how many of these cells are monocytic MDSC and how many are monocytes in which HLA-DR has been downregulated as suggested by the authors.

In addition, there is evidence that MDSC of proinflammatory potential can be released from the bone marrow in inflammation [31]. There is so far no clear consensus on their eventual phenotype but these new marrow derived cells are initially characterised as Early stage MDSC (eMDSC), which do not at first express lineage markers but do express CD33 and would thus be susceptible to SARS-CoV-2 SGP manipulation until the virus was cleared (Fig. 3). Proinflammatory MDSC are recognised in murine and human arthritis and in IBD, where they suppress T cell proliferation, as do mature MDSC, but also strongly promote Th17 responses [31–33].

Analysis of immune responses in severe Covid-19 infection identified two distinct groups [30]. Around a quarter developed a
macrophage activation syndrome with hypercytokinaemia and hyperferritinaemia in association with reduced total neutrophils and monocytes compared to persons with milder disease. Three quarters showed preservation of circulating cell numbers, with a state of chronic immune deviation but without macrophage activation syndrome. This association of reduced circulating cells with a hyperinflammatory response is consistent with bone marrow suppression, where release of new MDSC is prevented. By contrast, the prolonged state of immune suppression with immunopathology is explicable by viral SGP stimulation of the newly released proinflammatory eMDSC (Fig. 3).

Potential contribution to neuropathy and CNS disease

There is increasing evidence that SARS-CoV-2 may invade the central nervous system [34]. This would be most likely in severe disease with blood brain barrier disruption, and SARS-CoV-2 SGP would show tropism for CD33-expressing microglia.

A common presentation of Covid-19 disease is anosmia (loss of smell) with ageusia (loss of taste). It has been postulated that the virus might gain access through the sieve-like barrier at the cribriform plate, in proximity to the olfactory bulb [34]. Penetration of a CD33 binding SGP would potentially induce activation of CD33-expressing microglia within the olfactory bulb to cause these symptoms. This would not require ingress of whole viral structures and could occur even if blood brain barrier function was intact elsewhere.

Potential contribution to ischaemia and vascular thrombosis

In severe Covid-19 infection there is a significant increase of venous and arterial thrombosis [2]. Several mechanisms are likely to contribute to this. A CD33-r Siglec binding viral SGP would provide a further and independent risk factor for vascular thrombosis.

Analysis of 274 circulating cytokines in diabetic patients with critical limb ischaemia identified soluble Siglec-5 as the outstandingly increased marker, and confirmed this in a large second cohort, which excluded confounding risk factors [35]. Soluble Siglec-5 concentrations were considerably more than an order of magnitude greater than reported previously in healthy controls and patients with SLE [36]. The source was identified as irregularly-shaped Siglec-5+ cells that were present within atherosclerotic plaques but not normal vascular endothelium [35]. These cells were not further characterised, and thus may have been either Siglec-5+ macrophages or Siglec-5+ MDSC. The mechanism by which Siglec-5 contributes to the progression of vascular ischaemia has yet to be determined, but there is clear potential for modulation of the Siglec-5+ cells within existing vascular atherosclerotic plaques by such a Siglec-5 binding viral SGP.

Potential contribution to multisystem inflammatory syndrome in children (MIS-C)

There has been recent recognition of a Covid-19 associated syndrome of multisystem inflammation in previously healthy paediatric
patients, usually without the initial presentation with respiratory dis-
ease seen in adults. By contrast, gastrointestinal symptoms were noted
in around 90% of cases in both the UK and USA multicentre cohorts
[37–38]. What is notable about paediatric cases of Covid-19 infection is
that SARS-CoV-2 is more readily detected in faeces than the respiratory
tract [39]. There is now evidence that the virus can productively infect
enterocytes, which strongly express the ACE-2 receptor. [40]. I suggest
that the lack of respiratory symptoms at presentation may point to
preferential infection via the gastrointestinal tract in children. The
subsequent mechanism of disease would then be as for complicated
adult disease (Figs. 1-3), but without the dominance of respiratory
symptoms seen in adult disease.

In support of this, there was evidence of ethnic predisposition in
both cohorts. The UK patients showed significant overrepresentation of
Afro-Caribbean and Asian children (47% and 28% of the cohort re-
spectively, compared to 8% and 7% of the overall UK population) [37].
The large USA cohort had ethnicity data on 147 children, of whom only
35 were White, non-Hispanic [38]. While most children had no re-
cognised comorbidities, 37% of the US children for whom data was
available had diagnosed or BMI-based obesity while the UK group
showed a significant increase in the observed to expected weight ratio.
Thus, a significant comorbidity in children may be an increase in MDSC
cells due to overweight. It is also notable that MDSC populations are
increased in children with atopic rhinitis [41] and asthma [42].

Features not explained by the model

The relative susceptibility of males is not explained by this, and the
mechanism is more likely to relate to a distinct antiviral immune re-
sponse (Fig. 1). TLR7 responds to intracellular viral RNA in innate
immune cells, and plasmacytoid dendritic cells of females produce more
antiviral type-1 interferons than do males [43], related to the number of
X chromosomes and serum testosterone production [44]. This may
underpin sex-related symptomatic differences in RNA viral infections
more generally, but may have a fundamentally more important impact
with a virus as virulent as SARS-CoV-2.

Testing predictions of the model

This model of SARS-CoV-2 pathogenesis can rapidly be supported or
excluded. Such interaction could be confirmed or excluded by genetic
analysis of persons with severe or fatal illness compared to the less
affected.

Genetic testing would be predicted to show:

1. Persons with homozygous Siglec-14 null allele would have higher
incidence of severe disease than those Siglec-5 + Siglec 14 +, with
heterozygotes intermediate. Preterm delivery would be more
common in Siglec-14 null women, as in GBS infection.

2. Persons of CD33 rs3865444 CC allele, when stratified by disease
susceptibility, would have higher incidence of severe disease than
those with CD33 rs3865444 TT allele.

Analysis of blood taken from affected persons would be predicted
to show:

3. Increased numbers of CD33 MDSC at presentation in those who go
on to develop severe disease.

4. Expanded numbers of CD33 MDSC cells in severe disease, char-
acterised as CD33 + CD11b + HLA-DRlow/-, producing proinflammatory
cytokines in persons with late-phase responses with immune deviation,
implicating a Th17-skewed response. Conversely, these cells would be at
low level in persons with macrophage activation syndrome and
hyperferritinaemia.

5. Increased serum Arginase-1 and decreased arginine in severe dis-
ease, with increased percentage of TCR-ζ low T cells.

6. Increased numbers of early stage CD33 + Siglec-5 + MDSC
(CD14 +/− CD15 +/−) producing proinflammatory cytokines in persons
with late-phase responses with immune deviation, in association
with a Th17-skewed response. Conversely, these cells would be at
low level in persons with macrophage activation syndrome and
hyperferritinaemia.

7. Increased circulating Siglec-5 in persons with Covid-19 induced
vascular disease.
Glycobiological testing of Siglec binding

Proceeding from the direction of assessing in vitro SGP binding to cell lines or tissues suffers from the disadvantage that glycan expression is known to be modulated by enzymes within the Golgi apparatus of host cells during viral replication [12]. This may lead to impaired glycan maturation resulting in shorter glycan chains [12]. Thus, predicted glycans may not be representative of those functioning in vivo to mediate pathogenesis. However, detection of the footprints of Siglec-defined immunopathology would provide imperative for such extensive studies to be undertaken in order to characterise binding sites.

Supporting data

Prediction 4 appears to have been fulfilled, as MDSC populations (CD33+ but including both CD14+ monocyteic and CD15+ granulocytic MDSC) were increased from 0.3% (IQR 0.13–2.13) in healthy donors to 47.5% (IQR 28.4–65.6%) in Covid-19 infection [45]. Further characterisation by the same group has demonstrated massive expansion of MDSC in 18 patients, making up to 90% of total peripheral blood mononuclear cells (PBMC) in severe disease and 25% in mild disease [46]. The frequency of these MDSC, largely CD15+ in this cohort, declined during recovery, with reduction of TGF-β. These cells demonstrated potent in vitro suppressive function on T cell activation and cytokine production.

This extraordinary percentage of MDSC in Covid-19 infection contrasts with the increase of MDSC to 5–10% of PBMC in dengue fever, where they have been implicated in disease outcome [47]. This is a strong pointer towards a specific mechanism of induction, unique to Covid-19 infection.

Prediction 6 is supported by evidence that proinflammatory MDSC of immature phenotype occur in human and murine arthritis, and strongly promote Th17 type responses [31–32]. The cytokine storm in severe Covid-19 infection has indeed been characterised to be of Th17 type [48], with over 30% of total CD4 cells being of Th17 phenotype (CD4+CCR6+) in one well-studied case with fatal outcome [49]. The patient died on day 14 of illness, suggesting that such proinflammatory MDSC are released within the first two weeks of infection.

Therapeutic implications

If predictions based on this model are confirmed, inhibition of SARS-CoV-2 secreted glycoprotein interaction with host CD33-related Sigslec should be of clinical benefit. If the testing predictions are confirmed, the next stage would be to characterise the binding, which may be mediated by a single SGP or by two.

If the CD33-related Siglec-binding SGP is of sialyl Tn type, there may well be an existing sialyl Tn monoclonal that serendipitously blocks SGP binding to Siglecs. This would potentially be therapeutic.

If not, characterisation of SGP-Siglec binding would allow design of a small molecule that blocks interaction (possibly two), which would then be suitable for creating blocking immunoglobulin- (Ig)-fusion protein(s) for clinical use. In due course, this might allow persons who fail to respond to immunisation to be pre-treated to block Siglec binding sites, allowing them to be exposed to small infecting doses of SARS-CoV-2 in clinically controlled circumstances and thus generate a broad immune response, including to the pathogenic glycan determinants.

Conclusion

The clinical course of Covid-19 infection is highly variable. The currently enigmatic determinants of disease severity can be fully explained on the basis of viral manipulation of host CD33-related Siglecs. There is evidence that both CD33 and Siglec-5 (thus also Siglec-14) bind similar sialylated ligands, and that sialylated Tn ligands induce expansion and activation of CD33 MDSC. Both virally induced NLRP3 inflammasome inhibition and expansion of CD33 MDSC have been identified in other viruses. However, the magnitude of the latter response is dramatically greater in Covid-19 infection and this appears to be the dominant innate immune response. Confirmation of this mechanism through simple and accessible testing would provide a clear target for therapeutic manipulation. It is possible that specific therapeutic agents already exist, because of the increasing recognition of the importance of MDSC immunosuppression in the pathogenesis of cancers.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

I confirm that I have no conflicts of interest relating to the article entitled Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14. Simon Murch PhD FRCP FRCPC

References

[1] Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020;24:422.
[2] Zhuang Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020 Apr 23;50163–453(20):30234–6.
[3] Chang YC, Nizet V, Siglecs at the Host-Pathogen Interface. Adv Exp Med Bio 2020;1204:197–214.
[4] Varzi A, Angata T. Siglecs—the major subfamily of I-type lectins. Glycobiology 2006;16:18–27R.
[5] Bornhofft RF, Goldammer T, Rehl A, Galaska SP. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins. Dev Comp Immunol 2018;86:219–31.
[6] Padler-Karavani V, Hurtado-Ziola N, Chang YC, Sonnenburg JL, Ronaghy A, Yu H, et al. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. PASEJ 2014;4:28:1280–93.
[7] Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT, et al. CD33 Alzheimer’s disease risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 2013;33:13320–5.
[8] Ali SR, Fong JJ, Carlin AF, Busch TD, Linden R, Angata T, et al. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J Exp Med 2014;211:1231–42.
[9] Brinkman-Van der Linden EC, Varzi A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. J Biol Chem 2000;275.
[10] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020;181:281–92.
[11] Shahjahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 2020 May 4. pii: cwaa452. doi: 10.1093/glycob/cwaa452.
[12] Watanabe Y, Allen JD, Wappn D, McEllan JS, Crispin M, Site-specific glyc an analysis of the SARS-CoV-2 spike. Science 2020 May 4. pii: eabb9983. doi: 10.1126/science.abb9983.
[13] Xioo X, Dimitrov DV. The SARS-CoV-2 Glycoprotein. Cell Mol Life Sci 2020;67:2428–30.
[14] Zhao C, Zhao W, NLRP3 Inflammasome-A Key Player in Antiviral Responses. Front Immunol 2020;11:211.
[15] Taxman DJ, Huang MY, Ying JP. Inflammasome inhibition as a pathogenic stealth mechanism. Cell Host Microbe 2010;8:8–11.
[16] Tsai CM, Riestra AM, Ali SR, Fong JJ, Liu JZ, Hughes G, et al. Siglec-14 Enhances NLRP3-Inflammasome Activation in Macrophages. J Innate Immun 2020;12:333–43.
[17] Yamaana K, Mato Y, Angata T, Narimatsu H. Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology 2009;19:841–6.
[18] Angata T, Ishii T, Motegi T, Soto PC, et al. Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci 2013;70:3199–210.
[19] Graustein AD, Horne DJ, Fong JJ, Schwarz F, Mefford HC, Peterson GJ, et al. The Transactivation of NLRP3 by CD33-related Siglecs. Cell 2020;181:281–92.
[20] Treu RC, MDSC; The Most Important Cell You Have Never Heard Of. Trends Pharmacol Sci 2019;40:4–7.
[21] Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012;144:250–68.
[22] Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, et al.
Blood CD33(+)/HLA-DR(low/-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 2013;93:633–7.

[23] Lehle FJN, Kaufmann J, Singh A, Fromm K, Teschner AC, Pischel S, et al. Myeloid-derived suppressor cells modulate B-cell responses. Immunol Lett 2017;188:108–15.

[24] Dar AA, Patil RS, Pradhan TN, Chaukar DA, D'Cruz AK, Chipulkar SV. Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma. Cancer Immunol Immunother 2020;69:1071–86.

[25] Bao Y, Mo J, Ruan L, Li G. Increased monocytic CD14(+)HLA-DRlow/- myeloid-derived suppressor cells in obesity. Mol Med Rep 2015;11:2322–8.

[26] Fernández-Ruiz JC, Galindo-De Ávila JC, Martinez-Fierro ML, Garza-Veloz I, Cervantes-Villagrana AR, Valtierra-Alvarado MA, et al. Myeloid-Derived Suppressor Cells Show Different Frequencies in Diabetics and Subjects with Arterial Hypertension. J Diabetes Res 2019;2019:1568457.

[27] Scrimini S, Pons J, Agustí A, Soriano JB, Cosio BG, Torrecilla JA, et al. Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respir Med 2013;107:1895–903.

[28] Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, et al. CD33 Alzherimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013;16:848–50.

[29] Wang Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fetal viral shedding. Nat Med 2020;26:502–5.

[30] Lamers MM, Beumer J, van der Vaart J, Knoops K, Puscheck J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020;369:50–4.

[31] Zhang H, Wang S, Huang Y, Wang H, Zhao J, Gaskin F, et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of collagen-induced arthritis through manipulating Th17 cell differentiation. Clin Immunol 2015;157:175–86.

[32] Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis 2016;75:278–85.

[33] Kim YJ, Chang SY, Ko HU. Myeloid-derived suppressor cells in inflammatory bowel disease. Curr Med Res Opin 2015;31:105–11.

[34] Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci 2020;11:1206–9.

[35] Zhang YL, Luan B, Wang XF, Qiao JY, Song L, Lei RR, et al. Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development. PLoS ONE 2013;8:e63775.

[36] Agrati C, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ 2020 Jun;8:1–12. https://doi.org/10.1038/s41418-020-0572-6.

[37] Davies P, Evans C, Kanthimathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study.Lancet Child Adolesc Health 2020 Jul 9; S2352-4642(20)30215-7.

[38] Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 2020;383:334–46.

[39] Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fetal viral shedding. Nat Med 2020;26:502–5.

[40] Lamers MM, Beumer J, van der Vaart J, Knoops K, Puscheck J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020;369:50–4.

[41] Zahran AM, Saad K, Elsayh KI, Abdelmoghny A, Aboul-Khair MD, Sobby A, et al. Myeloid-Derived Suppressor Cells and Costimulatory Molecules in Children With Allergic Rhinitis. Ann Otol Rhinol Laryngol 2019;128:128–34.

[42] Zhang YL, Luan B, Wang XF, Qiao JY, Song L, Lei RR, et al. Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development. PLoS ONE 2013;8:e63775.

[43] Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006;177:2088–96.

[44] Webb K, Peckham H, Radziszewska A, Menon M, Oliveri P, Simpson F, et al. Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration. Front Immunol 2019;9:3167.

[45] Bordoni V, Sacchi A, Cimini E, Notari S, Grassi G, Tartaglia E, et al. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19. Clin Infect Dis 2020 May 15. pii: ciaa577. doi: 10.1093/cid/ciaa577.

[46] Agrati C, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ 2020 Jun;8:1–12. https://doi.org/10.1038/s41418-020-0572-6.

[47] Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fetal viral shedding. Nat Med 2020;26:502–5.